JAIDS Journal of Acquired Immune Deficiency Syndromes:
A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South Africa
Mosam, Anisa MBChB, MMed, PhD*; Shaik, Fahmida MBChB, MMed†; Uldrick, Thomas S. MD, MS†,‡; Esterhuizen, Tonya MSc§; Friedland, Gerald H. MD‖; Scadden, David T. MD¶; Aboobaker, Jamila PhD, FRCP*; Coovadia, Hoosen M. MD#
Departments of *Dermatology; and
†CAPRISA, University of KwaZulu-Natal, Durban, South Africa
‡Mailman School of Public Health, Columbia University, New York, NY
§Department of Bioethics, University of KwaZulu-Natal, Durban, South Africa
‖Friedland AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University, New Haven, CT
¶Cancer Center and AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA
#Maternal Adolescent and Child Health [MatCH], University of the Witwatersrand, Johannesburg, South Africa.
Correspondence to: Anisa Mosam, MBChB, FC, MS, PhD, Department of Dermatology, Rm 327 3rd Floor Medical School, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Private Bag X 7, Congella, 4013 Durban, South Africa (email: email@example.com).
T. S. Uldrick is now with the HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD.
Supported by the National Research Foundation Thuthuka Grant GUN 2054349, National Cancer Institute AIDS Malignancy Consortium Grant Supplement 14, an AIDS Community Research Initiative of America Grant, and a Training Supplement to the Columbia University-Southern African Fogarty AIDS International Training and Research Programme, Fogarty International Center, National Institutes of Health (grant # D43TW00231), and the Irene Diamond Fund and Doris Duke Charitable Foundation. Triomune donated by Cipla-Medpro.
Presented in part as an oral presentation at the 17th Conference on Retroviruses and Opportunistic Infections, February 17, 2010, San Francisco, CA.
The authors have no funding or conflicts of interest to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
Authors' Contributions: A. Mosam designed study, cared for patients, analyzed data, and wrote manuscript. F. Shaik cared for patients, analyzed data, and wrote manuscript. T. Uldrick analyzed data and wrote manuscript. T. Esterhuizen analyzed data. G. H. Friedland, D. T. Scadden, J. Aboobaker, and H. M. Coovadia assisted in study design and writing of the manuscript.
Received November 23, 2011
Accepted February 22, 2012
Background: The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-Saharan Africa is unknown. With large-scale rollout of highly active antiretroviral therapy (HAART) in South Africa, we hypothesized that survival in HIV-KS would improve and administration of chemotherapy in addition to HAART would be feasible and improve KS-specific outcomes.
Methods: We conducted a randomized, controlled, open-label trial with intention-to-treat analysis. Treatment-naive patients from King Edward VIII Hospital, Durban, South Africa, a public-sector tertiary referral center, with HIV-KS, but no symptomatic visceral disease or fungating lesions requiring urgent chemotherapy, were randomized to HAART alone or HAART and chemotherapy (CXT). HAART arm received stavudine, lamivudine, and nevirapine (Triomune; CXT arm received Triomune plus bleomycin, doxorubicin, and vincristine every 3 weeks. When bleomycin, doxorubicin, and vincristine were not available, oral etoposide (50–100 mg for 1–21 days of a 28-day cycle) was substituted. Primary outcome was overall KS response using AIDS Clinical Trial Group criteria 12 months after HAART initiation. Secondary comparisons included time to response, progression-free survival, overall survival, adverse events, HIV control, CD4 reconstitution, adherence, and quality of life.
Results: Fifty-nine subjects were randomized to HAART and 53 to CXT; 12-month overall KS response was 39% in the HAART arm and 66% in the CXT arm (difference, 27%; 95% confidence interval, 9%–43%; P = 0.005). At 12 months, 77% were alive (no survival difference between arms; P = 0.49), 82% had HIV viral load <50 copies per milliliter without difference between the arms (P = 0.47); CD4 counts and quality-of-life measures improved in all patients.
Conclusions: HAART with chemotherapy produced higher overall KS response over 12 months, whereas HAART alone provided similar improvement in survival and select measures of morbidity. In Africa, with high prevalence of HIV and human herpes virus-8 and limited resources, HAART alone provides important benefit in patients with HIV-KS.
Kaposi sarcoma (KS) is one of the commonest AIDS-defining malignancies. KS incidence decreased in the West with the availability of highly active antiretroviral therapy (HAART),1 but it has increased in sub-Saharan Africa2 due to high rates of HIV-1 and human herpes virus-8 coinfection, overburdening already frail health care systems. HIV-associated KS (HIV-KS) can cause substantial morbidity and mortality, which may be improved by chemotherapy. Most studies of chemotherapy for HIV-KS have been evaluated in the United States and Europe.3–8 PEGylated liposomal doxorubicin and paclitaxel have response rates ranging from 46% to 76% in the HAART era, but they are not considered World Health Organization (WHO) essential drugs9 and are unavailable in many resource-poor settings.3 In industrialized countries, HAART is usually combined with chemotherapy for advanced HIV-KS. However, prospective evaluation of HAART alone for the treatment of HIV-KS has been limited,7 and its efficacy in advanced HIV-KS is unknown.
Before the availability of HAART in sub-Saharan Africa, HIV-KS mortality was high. In a prospective study in Zimbabwe in the 1990s comparing palliative chemotherapy, radiation, and supportive care in 470 HIV-KS patients in the absence of the available HAART, the 12-month overall survival (OS) was only 30%–40%.10 Similar outcomes were seen in KwaZulu-Natal (KZN), South Africa.11 In countries where HAART became widely available in 1996, OS of HIV-KS patients dramatically improved,12 and HAART has become essential in HIV-KS management. With the availability of HAART in the public sector of South Africa in 2003, we sought to more fully define the outcomes achieved with HAART in African patients with this common AIDS-defining malignancy, including those with advanced disease. Additionally, we hypothesized that chemotherapy started soon after the initiation of HAART may further improve KS-specific outcomes with manageable toxicities.
Participants and Study Design
The Kaposi sarcoma AIDS AntiRetroviral Therapy (KAART) Trial is a prospective, single-center, randomized, open-labeled trial comparing HAART with HAART combined with early chemotherapy (CXT) for HIV-KS. Treatment-naive patients (no prior KS or HIV therapy) were recruited and enrolled from Dermatology Clinic at the King Edward VIII Hospital, Durban, a public sector tertiary referral center for approximately 10.3 million people in KZN, South Africa. Enrolled patients had proven HIV and histologically confirmed KS. Exclusion criteria included KS requiring urgent chemotherapy (ie, symptomatic visceral disease or fungating lesions), peripheral neuropathy, clinical congestive heart disease or ejection fraction <50%, neutrophil count of <1000 units per liter, hemoglobin < 9.0 gm/dL, platelet count of <75 × 109 per liter, serum creatinine >114.4 μmol/L, direct serum bilirubin >85 μmol/L, aspartate aminotransferase or alanine aminotransferase >2.5 times the normal range, and intensive phase of tuberculosis therapy. Patients were staged according to modified AIDS Clinical Trials Group (ACTG) criteria into “Good” and “Poor” risk groups, then randomized to HAART or CXT by 4-digit computer generated code. “Poor” risk subjects had any tumor, immune, or symptom (TIS) ACTG staging feature associated with poor survival in HIV-KS. These included high-risk tumor features (T1) (visceral disease, tumor-associated edema, or ulceration), advanced immune suppression (I1) (CD4 <150 cells/μL), or systemic features of AIDS (S1) (history of opportunistic infections, wasting, fevers, night sweats, poor performance status) (for ACTG Staging of KS, see Table 1, Supplemental Digital Content 1, http://links.lww.com/QAI/A307).13,14
The study was done in accordance with principles of the Declaration of Helsinki and in compliance with Good Clinical Practice guidelines, with ethical approval from the Nelson R. Mandela School of Medicine institutional review board. All subjects provided written informed consent. This protocol was registered at clinicaltrials.gov (NCT00380770).
HAART was fixed-dose combination of stavudine (40 mg), lamivudine (150 mg), and nevirapine 200 mg (Triomune; Cipla-Medpro, Capetown, South Africa). This regimen was determined by the availability to investigators through a donation from CIPLA during a period when antiretrovirals were unavailable in the public sector in South Africa and was the first available public sector HAART regimen in KZN. Patients who developed resistance or drug toxicity received a second-line HAART regimen. Chemotherapy consisted of doxorubicin (20 mg/m2 intravenously), bleomycin (10 U/m2 intravenously), and vincristine (1.4 mg/m2 intravenously, capped at 2 mg) (ABV)15 every 3 weeks, started within the first month of initiation of HAART, with the goal of continuing chemotherapy for 2 cycles beyond maximal response. This relatively low-cost regimen consists of agents on the WHO essential drug list.9 Patients randomized to CXT were referred to public sector Oncology Clinic for chemotherapy administration. Patients in the HAART arm with inadequate KS response by month 6 or progressive KS requiring chemotherapy before month 6 were considered “HAART treatment failures” and offered chemotherapy based on both clinician judgment and the evaluation of KS response using ACTG response criteria. Although planned protocol chemotherapy was ABV, oral etoposide (50–100 mg for 1–21 days of a 28-day cycle)16 was used as alternative therapy in the event of difficulties with chemotherapy drug supply or intravenous administration during the protocol. Dose modifications of HAART or chemotherapy were performed for toxicity or changes in renal function. Etoposide was started at 50 mg daily but could be escalated to 100 mg in patients in subsequent cycles with inadequate KS tumor regression and no limiting toxicities.
Monitoring and Response Evaluation
At baseline, KS was evaluated by physical examination, chest radiograph, and upper endoscopy. If indicated, bronchoscopy was performed. Endoscopy and chest radiography were repeated at 6 months in those with baseline visceral KS. Investigators in the Dermatology Clinic assessed the clinical response every 3 months through month 12. Response evaluations included lesion counts, measurement of the sum product of the diameters of 5 marker lesions, and assessment of nodularity. KS responses were graded as complete, partial, stable disease, and progressive disease using previously described ACTG criteria (for ACTG KS Response Criteria, see Table 2, Supplemental Digital Content 2, http://links.lww.com/QAI/A308).13,14 Partial response (PR) required at least 50% decrease in the number of lesions and/or sum product of the diameters of marker lesions and/or nodularity of lesions and no new lesions, whereas complete response (CR) required clinical resolution of all lesions and tumor-associated phenomenon. CR and PR were combined to determine the overall response rate (ORR).
Monitoring included history and physical examination, complete blood count, serum chemistry, CD4 count, and HIV-1 viral load (HIV-VL) performed at baseline, week 2, week 4, and then monthly for 12 months. HIV-VL was measured by RNA polymerase chain reaction (HIV-1 QT kit; Roche Diagnostics, Rotkreuz, Switzerland), and CD4 counts were performed by EpicsXL Flow Cytometer and tetraOne System (Beckman Coulter, Brea, CA). Toxicities were graded using Division of AIDS (DAIDS) toxicity scale. Adherence was assessed by a 7-day recall questionnaire,17,18 at week 2, week 4, and then monthly.
Previously validated quality-of-life (QOL) questionnaires (EORTC QOL-30),19,20 available in English and isiZulu, were completed at baseline and trimonthly. The questionnaire measures 6 functioning scales: physical, role, cognitive, emotional, social, and global QOL; and 9 symptom scales and/or items: fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial impact.20 Differences greater than 10 points in QOL scores were considered to be clinically important.21
Primary and Secondary Outcomes
Primary outcome was comparison between arms of the proportion of patients with a KS PR or better at month 12 compared with baseline. Secondary outcomes included comparisons between arms of progression-free survival (PFS; time from randomization to progressive disease or death), time to response (TTR; time from randomization to achievement of PR or better), OS, adverse events (including the immune reconstitution inflammatory syndrome [IRIS]), immunological and virologic parameters, adherence, QOL, and evaluation of modified ACTG prognostic criteria.
Detection of 30% absolute improvement in ORR from 0.3 to 0.6 at month 12 with the addition of chemotherapy (2-sided α = 0.05, β = 0.8) required 49 patients per arm. Assuming modest loss to follow-up, accrual goal was 120. Comparisons were based on intention-to-treat (ITT) analysis. Between arms, 12-month ORR, incidence of per-patient specific serious adverse events, and proportion of patients with undetectable HIV at month 12 were compared using Fisher exact test. TTR was compared between arms using the Mantel–Haenszel rate ratio. PFS and OS were evaluated using Kaplan–Meier methodology with log–rank test to compare arms. Multivariate analysis of ACTG TIS risk factors employed Cox regression. Difference in CD4 reconstitution between arms was evaluated with the Mann–Whitney test. We evaluated intragroup changes in QOL scores between baseline and month 12 (Wilcoxon signed-rank test), changes between baseline and month 12 QOL scores between the 2 groups (Mann–Whitney test), and the relationship between clinical responses and global QOL (Kruskal–Wallis test). Given multiple comparisons in QOL analysis, P < 0.01 was considered statistically significant, whereas 0.01 < P < 0.05 represented important trends. In addition to ITT analyses, secondary planned as treated analysis was performed for 12-month ORR and OS.
Role of the Funding Sources
Study planning, design, implementation, analysis, and write-up were performed entirely by the investigators. Funders had no role in conceptualization, planning, design, analysis, or writing of this manuscript.
Study Subjects, Randomization, and Follow-up Events
From 2003 to 2009, 310 patients were screened; 112 were eligible, consented, and randomized (59 to HAART and 53 to CXT) and followed for up to 12 months (Fig. 1). Table 1 illustrates baseline demographic characteristics. Notably, 110 of 112 were black, 55% were women, 69% were from the urban area of Durban, and 31% were rural residents of KZN. Ninety-three percent were on poor risk based on modified ACTG criteria: 89% had advanced disease with a high tumor burden (T1), 54% had a CD4 count <150 cells per microliter (I1) (58% had CD4 <200 cells/μL), and 42% had inflammatory “B” symptoms or a history of opportunistic infection (S1), including a history of treated tuberculosis in 16 subjects.
Of patients assigned to HAART, 13 (22%) were “HAART treatment failures” and received chemotherapy, 10 between months 2 and 6, and 3 after month 6. Of patients randomized to CXT, 15 (28%) received HAART alone. Thirteen (86%) of these 15 died or were lost to follow-up before receiving chemotherapy. Patients randomized to CXT but not receiving chemotherapy had low baseline CD4 counts (median, 77 cells/μL), compared with those receiving chemotherapy (median, 249 cells/μL). Sixteen patients (31% of chemotherapy administered) received oral etoposide. Among patients receiving chemotherapy, the median number of cycles administered was 6 (interquartile range, 4–6). Five patients (4%) were lost to follow-up (Fig. 1).
Primary outcome was KS response at month 12. In the CXT arm, 9 (17%) had a CR and 26 (49%) had a PR for an ORR of 66%; 18 (34%) failed to respond. In the HAART arm, 4 (7%) had a CR and 19 (32%) had a PR for an ORR of 39%; 36 (61%) failed to respond. The absolute difference in ORR was 27% [95% confidence interval (CI), 9%–43%; Table 2]. Limiting analysis to the 100 subjects with T1 disease, ORR was 64% in the CXT arm and 36% in the HAART arm (P = 0.009, Fisher exact test).
One-year PFS in the CXT arm was 56% versus 31% in the HAART arm [hazard ratio (HR) = 0.52; 95% CI, 0.31–0.88; Fig. 2A]. Results were similar after limiting PFS analysis to T1 patients (HR = 0.54; 95% CI, 0.31–0.93) Furthermore, patients randomized to CXT obtained earlier tumor regression compared with HAART [TTR rate ratio, 2.8 (95% CI, 1.7–4.4); Fig. 2B]. In an as-treated analysis, the proportion of patients receiving HAART alone that achieved PR or better at month 12 month was 38%; for those receiving HAART and at least 1 cycle of chemotherapy, it was 69% (74% for ABV, 56% for oral etoposide) (comparison of HAART to HAART and any chemotherapy, P = 0.001, Fisher exact test).
Despite most patients being poor risk, 12-month OS was 77%, with no significant difference between arms (P = 0.49; Fig. 2C). This remained true after correcting for TIS risk factors (P = 0.33), in a secondary as treated analysis (P = 0.1), and when limiting analysis to T1 subjects (OS = 74%; P = 0.54). Of 26 deaths, 12 died of documented progressive KS (46% of deaths), 10 of these met criteria for KS-IRIS. Nine of the 12 (3 in the HAART arm and 6 in the CXT arm) died before receiving chemotherapy. Two additional patients with pulmonary KS died of respiratory symptoms of unknown etiology. Two died of liver failure, 2 of documented infection, and 8 of other causes. Patient's 12-month OS was evaluated based on the number of ACTG risk features. Multivariate logistic regression including established risk factors effectively risk-stratified patients (P = 0.03), validating the modified ACTG staging system in our population. In this cohort in which 89% had T1 disease, S1 [including history of tuberculosis in 16 (36%) of 44 S1 patients], emerged as the most important TIS predictor of 12-month OS, with borderline statistical significance on multivariate analysis (univariate HR of death, S1 compared with S0 = 2.4, P = 0.02; multivariate analysis, HR = 2.0, P = 0.08). Baseline CD4 count <150 cells per microliter was a less powerful predictor of 12-month OS (univariate HR of death for I1 compared with I0, = 1.9, P = 0.1; multivariate analysis, HR = 1.6, P = 0.24) than using CD4 count <100 cells per microliter as a cutoff (univariate HR of death for CD4 <100 cells/μL compared with ≥100 cells/μL = 2.6, P < 0.01; multivariate analysis, HR = 2.74, P < 0.01; TIS model using I1 = CD4 <100 cells/μL, P < 0.01) (Fig. 2D). Additionally, female sex was an independent risk factor for death in univariate analysis (HR =2.6; P = 0.02), and after correcting for other TIS risk factors (CD4 <100 cells/μL cutoff) and treatment arm (HR = 2.6; P = 0.04).
The commonest severe adverse events (per patient) were abnormal liver function tests (16%), anemia (17%), and infections (22%). There were no statistically significant differences in the number and proportion of severe adverse events between the arms (Table 3). KS-IRIS (for definition of KS-IRIS, see Table 2, Supplemental Digital Content 2, http://links.lww.com/QAI/A308) was diagnosed in 23 patients (21%). Ten of these, including 9 with visceral KS, died. Pulmonary KS-IRIS contributed to 6 of these deaths. Overall, 37% of all deaths occurred in patients who met criteria for KS-IRIS. There were no significant differences between the arms in the occurrence or mortality attributed to KS-IRIS.
Adherence and HIV-Related Outcomes
Seven-day recall was performed on 1070 (91%) of 1175 total visits. In the HAART arm, patients reported 100% adherence in 92.4% of visits versus 89.5% of visits in the CXT arm (P = 0.8, Fisher exact test). Seven patients (12%) in the HAART arm and 5 (9%) in the CXT arm changed HAART due to toxicity or virologic failure. Two in the HAART arm changed HAART regimen on 2 occasions. HIV virologic control was very good, with 82% of patients with HIV <50 copies per milliliter at month 12 and no difference between the arms (P = 1.0). CD4 reconstitution was seen in most patients. In patients completing 12 months of follow-up, median increase from baseline to month 12 was 129 cells per microliter (range, −185 to +860) with no difference between the arms (P = 0.73) (median CD4 count and interquartile range: baseline, month 6, month 12, by arm; see Figure 1, Supplemental Digital Content 3, http://links.lww.com/QAI/A309).
QUALITY OF LIFE
QOL improved significantly from baseline to month 12 on HAART. In the entire cohort, median global health score (perfect score = 100) was 50 at baseline and 67 at month 12 (P < 0.001). CR or PR by month 12 was associated with increased global health score (P < 0.001). Across subjects, improvements in emotional (P < 0.001), social (P = 0.003), and cognitive functioning (P < 0.001) were noted. Symptom scales demonstrating statistically significant improvements (P < 0.01) were fatigue, appetite loss, pain, dyspnea, insomnia, constipation, diarrhea, and financial problems. Comparing arms, a trend toward improved role functioning (perfect score = 100) favored the CXT arm (median change HAART = 0, CXT = +17; P = 0.011). Improvement in pain (perfect score = 0, median change HAART = -16.7, CXT = -33.3; P = 0.1) and overall QOL (median change HAART = 12.5; CXT = 16.7; P = 0.08) were also greater in the CXT arm. Comparisons between the arms were not statistically significant.
This is the first randomized controlled trial using HAART in African patients with HIV-KS. We compared HAART alone with HAART combined with chemotherapy for KS efficacy, OS, safety, control of HIV, adherence, and QOL improvement. Patients were treatment naive, 89% had advanced (but not immediately life threatening) KS, and 58% had CD4 <200 cells per microliter. This is the population most likely to be in need of therapy for both diseases in Africa. Randomization to CXT improved 12-month ORR (66% in CXT arm versus 39% HAART arm). Seventy-seven percent of patients were alive at 12 months, and patients randomized to HAART alone had similar OS compared with those randomized to HAART and chemotherapy.
The KAART study provides much-needed, randomized, controlled trial evidence regarding therapy for HIV-KS in sub-Saharan Africa. Thirty-nine percent responded to HAART alone, providing the best estimate of efficacy of HAART alone in the treatment of HIV-KS treatment-naive patients with advanced KS. ORR with HAART alone compares favorably with that seen in a Spanish study (ORR = 20%), despite a high proportion of T1 patients in the KAART study (T1 15% in the Spanish study versus 89% in KAART),7 perhaps reflective of differences in HIV resistance profiles, other unmeasured KS associated factors, and adherence. The ORR seen in the CXT arm (66%) is superior to a large Zimbabwean study, which administered ABV without the benefit of HAART (49%).10
Importantly, we demonstrated excellent 12-month OS (77%) in this high-risk cohort, comparing favorably with the <40% 12-month OS noted in the Zimbabwean study10 and in line with OS estimates across a range of HIV-KS stages in industrialized countries (24-month OS, 58%–84%)8,12,21,22 after the broad availability of HAART. In Africa, modified ACTG staging remains useful for prognosis in HIV-KS (P = 0.03). Systemic illness is a significant prognostic factor of OS. History of tuberculosis was the commonest comorbidity (36%), and management of concurrent KS and tuberculosis remains a particularly important challenge in sub-Saharan Africa. Active screening and therapy for tuberculosis are important steps to reduce morbidity and mortality of HIV-KS patients. HIV-KS patients with CD4 <100 cells per microliter are also at an increased risk of dying in the first 12 months of therapy and may require extra attention to supportive care.
Although KAART demonstrates that HAART with or without chemotherapy improves 12-month OS in South African treatment-naive patients with HIV-KS (77% versus 30%–40% historical controls), additional studies are needed. KS-IRIS developed in 23 patients and contributed to mortality in 10. Improved understanding of the risk factors and underlying pathophysiology of KS-IRIS,23,24 improved recognition and earlier use of chemotherapy, and novel treatment strategies could lead to further improvements in survival for these high-risk patients.
KAART had a female preponderance, reflecting the HIV and HIV-KS epidemics in South Africa. Women had poorer 12-month survival not explained by ACTG prognostic factors or treatment arm. This finding builds on retrospective observations that women with HIV-KS have more aggressive disease and inferior outcomes than men25–27 and is the first prospective study demonstrating inferior outcomes in women despite comparable therapy.
Notably, HIV and HIV-KS outcomes observed in KAART were obtained using a nonnucleoside reverse transcriptase inhibitor–based regimen. Additional HAART regimens, including protease inhibitor–based regimens, are now available in the public sector in South Africa. Although controlling HIV28 viremia and allowing for immune reconstitution29 are the primary goals in using HAART to treat HIV-KS,30–32 evaluation of additional anti–human herpes virus-8 effects of specific antiretroviral agents remains an area of active research.33,34
KAART is the first study to document the influence of HAART, with or without chemotherapy, on QOL in patients with HIV-KS. Patients benefited significantly in overall global health status, functioning, and symptom scales. Most dramatic improvements were reported for pain, fatigue, insomnia, constipation, and financial problems. There were no statistically significant differences in QOL measures between the arms; however, obtaining PR or better was associated with improvement in global QOL, validating tumor regression as an important palliative goal in advanced HIV-KS.10,35
A related question is whether addition of chemotherapy to HAART causes unnecessary toxicity or otherwise compromises HIV-directed care. Overall, the adverse event profile was manageable in both arms and not statistically different. The commonest adverse events experienced were hepatitis, paresthesias, anemia, diarrhea, vomiting, and pneumonia. The majority were grade 1–2 toxicities; severe toxicity rates did not differ significantly between the arms. Given cross over between arms and the use of 2 separate chemotherapeutic regimens, the lack of difference of severe toxicities between the arms should not be strictly interpreted. Patients receiving chemotherapy in addition to HAART for HIV-KS require monitoring for known chemotherapy-specific adverse events. Larger studies are required to further define the toxicity profile of patients eceiving chemotherapy for HIV-KS in sub-Saharan Africa. HAART regimen changes due to drug toxicity were noted in 8 (7%) of 112 patients, the commonest being nevirapine hepatitis (4 of 122). Less common were peripheral neuropathy and anemia. Chemotherapy did not significantly worsen adherence. This is crucial, as high pill burden is an important issue in HIV care in resource-limited settings. Patients likely benefited from frequent support to achieve and maintain adherence. CD4 increase and HIV-VL decay were comparable between the arms.
A limitation of the study was that some patients randomized to CXT did not receive the intended ABV due to a variety of common problems with chemotherapy administration in sub-Saharan Africa. Despite this introduced heterogeneity, which would be expected to weaken findings in ITT analysis, being randomized to CXT had benefits with respect to tumor response. The number needed to treat with chemotherapy in addition to HAART to obtain a PR or better by 12 months was 3.7 (95% CI, 2.2–11.9). The number needed to treat to prevent one patient from disease progression at 6 months was 3.3 (95% CI, 2.3–5.8). Importantly, findings from the KAART study may not be generalizable to HIV-KS patients with symptomatic visceral disease or fungating lesions. Furthermore, the KAART study was not designed to evaluate optimal chemotherapy in patients with HIV-KS. To address this, another randomized controlled trial of several chemotherapeutic regimens for African patients with advanced HIV-KS is planned (NCT01435018).
HAART is essential in improving survival in patients with HIV-KS in South Africa, whereas chemotherapy improves KS-specific responses. HAART controls HIV and may be sufficient in managing KS in a sizable proportion of treatment naive HIV-KS patients, even those with T1 disease. This is of particular importance given the current unavailability of chemotherapy in many African settings, where KS remains the commonest malignancy. Effective therapy for KS remains an important goal for decreasing the morbidity in African patients with HIV-KS. Chemotherapy has a beneficial role in some HIV-KS patients, and the addition of chemotherapy to HAART results in an improved ORR, TTR, and PFS in HIV-KS. Further studies of HAART combined with additional KS therapies are warranted for African patients with advanced HIV-KS as is more widespread availability and the use of established chemotherapy for patients with symptomatic disease.
The authors acknowledge G. Ganyile, K. Hoosen, U. Bodasing and H. Dawood for their invaluable assistance; Qurraisha and Slim Abdool Karim for their advice, expertise, and support and Irene van Middelkoop for managing the database.
1. Jacobson LP, Yamashita TE, Detels R, et al.. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S34–S41.
2. Mosam A, Carrara H, Shaik F, et al.. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006). Int J STD AIDS. 2009;20:553–556.
3. Dedicoat M, Vaithilingum M, Newton R. Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst Rev. 2003;(3):CD003256.
4. Dupont C, Vasseur E, Beauchet A, et al.. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS. 2000;14:987–993.
5. Cattelan AM, Calabro ML, De Rossi A, et al.. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27:779–785.
6. Gill J, Bourboulia D, Wilkinson J, et al.. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma–associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr. 2002;31:384–390.
7. Martin-Carbonero L, Barrios A, Saballs P, et al.. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS. 2004;18:1737–1740.
8. Cianfrocca M, Lee S, Von Roenn J, et al.. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. 2010;116:3969–3977.
9. Sikora K, Advani S, Koroltchouk V, et al.. Essential drugs for cancer therapy: a World Health Organization consultation. Ann Oncol. 1999;10:385–390.
10. Olweny CL, Borok M, Gudza I, et al.. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. 2005;113:632–639.
11. Mosam A, Uldrick TS, Shaik F, et al.. An evaluation of the early effects of a combination antiretroviral therapy programme on the management of AIDS-associated Kaposi's sarcoma in KwaZulu-Natal, South Africa. Int J STD AIDS. 2011;22:671–673.
12. Biggar RJ, Engels EA, Ly S, et al.. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293–299.
13. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7:1201–1207.
14. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1997;15:3085–3092.
15. Gill PS, Rarick M, McCutchan JA, et al.. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med. 1991;90:427–433.
16. Evans SR, Krown SE, Testa MA, et al.. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002;20:3236–3241.
17. Mannheimer S, Friedland G, Matts J, et al.. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–1121.
18. Mannheimer S, Thackeray L, Huppler Hullsiek K, et al.. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20(2):161–169.
19. Aaronson NK. Assessment of quality of life and benefits from adjuvant therapies in breast cancer. Recent Results Cancer Res. 1993;127:201–210.
20. Aaronson NK, Ahmedzai S, Bergman B, et al.. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
21. Martin-Carbonero L, Palacios R, Valencia E, et al.. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis. 2008;47:410–417.
22. Lodi S, Guiguet M, Costagliola D, et al.. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102:784–792.
23. Letang E, Almeida JM, Miro JM, et al.. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in mozambique: a prospective study. J Acquir Immune Defic Syndr. 2010;53:589–597.
24. Uldrick TS, Wang V, O'Mahony D, et al.. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51:350–358.
25. Mosam A, Hurkchand HP, Cassol E, et al.. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. Int J STD AIDS. 2008;19:400–405.
26. Nasti G, Serraino D, Ridolfo A, et al.. AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:337–341.
27. Meditz AL, Borok M, MaWhinney S, et al.. Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe. J Acquir Immune Defic Syndr. 2007;44:306–308.
28. Martinez V, Caumes E, Gambotti L, et al.. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer. 2006;94:1000–1006.
29. Bihl F, Mosam A, Henry LN, et al.. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS. 2007;21:1245–1252.
30. Bower M, Weir J, Francis N, et al.. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS. 2009;23:1701–1706.
31. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol. 2004;22:399–402.
32. Nguyen HQ, Magaret AS, Kitahata MM, et al.. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008;22:937–945.
33. Gantt S, Carlsson J, Ikoma M, et al.. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother. 2011;55:2696–2703.
34. Uldrick TS, Polizzotto MN, Aleman K, et al.. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117:6977–6986.
35. Osoba D, Northfelt DW, Budd DW, et al.. Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: a randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine. Cancer Invest. 2001;19:573–580.
This article has been cited 4 time(s).
European Review for Medical and Pharmacological Sciences
Kaposi's sarcoma in HIV-positive patients: the state of art in the HAART-era
European Review for Medical and Pharmacological Sciences, 17():
Expert Review of Anticancer TherapyDo we still need chemotherapy for AIDS-associated Kaposi's sarcoma?Expert Review of Anticancer Therapy
Expert Review of Anti-Infective TherapyAssessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methodsExpert Review of Anti-Infective Therapy
Turkderm-Archives of the Turkish Dermatology and VenerologyMalignant Diseases of the Oral MucosaTurkderm-Archives of the Turkish Dermatology and Venerology
Kaposi sarcoma; AIDS; HIV; highly active antiretroviral therapy; South Africa
Supplemental Digital Content
© 2012 Lippincott Williams & Wilkins, Inc.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Highlight selected keywords in the article text.
Data is temporarily unavailable. Please try again soon.
Readers Of this Article Also Read